Amgen Inc. (AMGN)
Pre-Market:
| Previous Close | 328.35 |
| Open | 325.61 |
| Bid | 308.09 x 100 |
| Ask | 324.67 x 100 |
| Day's Range | 322.68 - 326.95 |
| 52 Week Range | 249.70 - 346.85 |
| Volume | |
| Avg. Volume | 1,945,568 |
| Market Cap | 174.428B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 55.87 |
| EPS (TTM) | 5.81 |
| Earnings Date | Oct 30, 2024 |
| Forward Dividend & Yield | 9.00 (2.77%) |
| Ex-Dividend Date | Aug 16, 2024 |
| 1y Target Est | 332.20 |
Investor's Business DailyWhy Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
Barrons.comAmgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk But one analyst argues that mounting competition in weight-loss drugs will make it harder for the stock to benefit. Truist analyst Srikripa Devarakonda downgraded Amgen to Hold from Buy on Monday, while raising the firm’s target for the stock price to $333 from $320. Like most pharmaceutical companies, Amgen trades much based on how it progresses in developing new drugs.
ZacksAmgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
